Berotralstat Hydrochloride Patent Expiration
Berotralstat Hydrochloride is Used for preventing attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. It was first introduced by Biocryst Pharmaceuticals Inc
Berotralstat Hydrochloride Patents
Given below is the list of patents protecting Berotralstat Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Orladeyo | US10662160 | Crystalline salts of a plasma kallikrein inhibitor | Nov 01, 2039 | Biocryst |
Orladeyo | US11117867 | Crystalline salts of a plasma kallikrein inhibitor | Nov 01, 2039 | Biocryst |
Orladeyo | US11618733 | Crystalline salts of a plasma kallikrein inhibitor | Nov 01, 2039 | Biocryst |
Orladeyo | US10125102 | Human plasma kallikrein inhibitors | Apr 07, 2035 | Biocryst |
Orladeyo | US10329260 | Human plasma kallikrein inhibitors | Mar 09, 2035 | Biocryst |
Orladeyo | US10689346 | Human plasma kallikrein inhibitors | Mar 09, 2035 | Biocryst |
Orladeyo | US11230530 | Human plasma kallikrein inhibitors | Mar 09, 2035 | Biocryst |
Orladeyo | US11708333 | Human plasma kallikrein inhibitors | Mar 09, 2035 | Biocryst |
Berotralstat Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List